Search Results - colon+cancer

5 Results Sort By:
Human T Cell Receptors for Treating Cancer
Abstract: T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit...
Published: 4/8/2024   |   Inventor(s): Richard Morgan, Nachimuthu Chinnasamy, Steven Rosenberg
Keywords(s): COLON CANCER, Hepatocellular cancer, MELANOMA, PROSTATE CANCER, SSX
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Abstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.  Investigators at the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li
Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Panaxynol as a new agent for cancer prevention and treatment
Reference #: 01618 The University of South Carolina is offering licensing opportunities for Panaxynol as a new agent for cancer prevention and treatment Background: National costs for cancer care were estimated to be $208.9 billion in 2020; particularly for colorectal cancer (CRC), the economic burden in the U.S. is estimated to be over $24 billion...
Published: 9/30/2024   |   Inventor(s): Angela Murphy, Lorne Hofseth
Keywords(s): cancer, cancer prevention, cancer treatment, Colon cancer, Natural product, polyps
Category(s): Biomedical and Life Sciences, Health Sciences
Prodrugs of Short-Chain Fatty Acids for Treatment of Intestinal Disorders and Colon Cancer
Current State of the Art: Colon cancer, IBS, Crohn’s disease and colitis present as some of the most difficult diseases to treat with the medications available currently. Treatment can be as drastic as surgery, chemotherapy, medications, such as cortisone, which can have sometimes serious and debilitating side effects. Colon cancer is treated with...
Published: 4/28/2020   |   Inventor(s): Vadivel Ganapathy, Puttur Prasad, Robert Martindale
Keywords(s): Colon Cancer, Inflammatory Bowel Disease, Ulcerative Colitis
Category(s): Therapeutics
HM74A/HM74 Ligands as Anti-Cancer and Anti-Diarrheal Drugs
Tech ID: 2007-030: Compositions Comprising a GPR109 Ligand for Treating Disorders of the Digestive Tract and/or CancerState of the Art: Top drugs for colon cancer include Xeloda (Genetech), Erbitux (Johnson and Johnson), Eloxatin (Sanofi), and Gleevec (Novartis). These four drugs ranked in the top 10 selling cancer drugs of 2011 and totaled ~$4 billion...
Published: 10/5/2020   |   Inventor(s): Vadivel Ganapathy, Puttur Prasad, Muthusamy Thangaraju, Gail Cresci
Keywords(s): Colon Cancer, Gene, Ligand
Category(s): Therapeutics